Abstract
The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.
MeSH terms
- AIDS Vaccines / genetics*
- AIDS Vaccines / immunology*
- Animals
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Disease Models, Animal
- Gene Products, gag / genetics
- Gene Products, gag / immunology
- Gene Products, nef / genetics
- Gene Products, nef / immunology
- Gene Products, rev / genetics
- Gene Products, rev / immunology
- Gene Products, tat / genetics
- Gene Products, tat / immunology
- HIV Antigens / genetics*
- HIV Antigens / immunology*
- HIV Envelope Protein gp160 / genetics
- HIV Envelope Protein gp160 / immunology
- HIV Infections / immunology*
- HIV Infections / prevention & control
- HIV Infections / therapy
- HIV Reverse Transcriptase / genetics
- HIV Reverse Transcriptase / immunology
- HIV-1 / genetics
- HIV-1 / immunology*
- Humans
- Leukemia Virus, Murine
- Mice
- Mice, Inbred C57BL
- Vaccines, Combined / genetics
- Vaccines, Combined / immunology
- Vaccines, DNA / genetics
- Vaccines, DNA / immunology*
- nef Gene Products, Human Immunodeficiency Virus
- rev Gene Products, Human Immunodeficiency Virus
- tat Gene Products, Human Immunodeficiency Virus
Substances
- AIDS Vaccines
- Gene Products, gag
- Gene Products, nef
- Gene Products, rev
- Gene Products, tat
- HIV Antigens
- HIV Envelope Protein gp160
- Vaccines, Combined
- Vaccines, DNA
- nef Gene Products, Human Immunodeficiency Virus
- rev Gene Products, Human Immunodeficiency Virus
- tat Gene Products, Human Immunodeficiency Virus
- HIV Reverse Transcriptase